Stoke Therapeutics (NASDAQ:STOK) Insider Sells $52,355.52 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,696 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $30.87, for a total value of $52,355.52. Following the completion of the transaction, the insider owned 23,460 shares of the company’s stock, valued at $724,210.20. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Barry Ticho also recently made the following trade(s):

• On Friday, December 5th, Barry Ticho sold 3,662 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total value of $114,767.08.
• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total value of $61,729.10.
• On Tuesday, December 2nd, Barry Ticho sold 2,006 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $59,738.68.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total value of $152,545.32.

Stoke Therapeutics Stock Down 0.6%

Shares of NASDAQ STOK traded down $0.18 during midday trading on Friday, reaching $30.87. The company had a trading volume of 602,753 shares, compared to its average volume of 917,923. The firm’s fifty day moving average price is $28.90 and its 200-day moving average price is $19.69. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $38.69. The stock has a market cap of $1.76 billion, a PE ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Wedbush lifted their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Canaccord Genuity Group increased their target price on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday. Finally, BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $31.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics in the 3rd quarter valued at $41,000. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Strs Ohio purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at approximately $150,000. Finally, Osaic Holdings Inc. raised its position in shares of Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after buying an additional 5,427 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.